Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Study Finds No Safety or Immunogenicity Differences in Patients Switching Patients Between Reference Biologics and Biosimilars

Oct 3, 2023

A PLOS One study found that there was no difference in the safety profiles or immunogenicity rates in patients who were switched and those who remained on a reference biologic or a biosimilar. The study examined unique studies and switch treatment periods for each reference biologic with an FDA approved biosimilar, including AbbVie’s Humira® (adalimumab), Amgen’s Epogen® (epoetin-alfa), Amgen’s Enbrel® (etanercept), Amgen’s Neupogen® (filgrastim), Sanofi’s Lantus® (insulin-glargine), Genentech/Biogen’s Rituxan® (rituximab) and Genentech’s Herceptin® (trastuzumab).

On 26 May 2023, a study published in JAMA Network Open found in a systematic review and meta-analysis that biosimilars of adalimumab, etanercept, and infliximab were associated with clinically equivalent effects in patients with rheumatoid arthritis compared with their reference biologics.